Gamaleya Research Institute
The first registered COVID-19 vaccine on the market. A viral two-vector vaccine based on the human adenovirus — a common cold virus — fused with the spike protein of SARS-CoV-2 to stimulate an immune response. Developed by Russian Gamaleya Research Institute of Epidemiology and Microbiology. Introduced into civil circulation from January 1, 2021.